Download PDF
Diabetologie und Stoffwechsel 2010; 5(2): R15-R28
DOI: 10.1055/s-0030-1247299
DuS-Refresher

© Georg Thieme Verlag Stuttgart ˙ New York

Therapie der diabetischen Dyslipoproteinämie

K. G. Parhofer1 , H.-C. Geiß1
  • 1Medizinische Klinik II, Klinikum der Universität München – Großhadern
Further Information

Publication History

Publication Date:
28 April 2010 (online)

Also available at
    Permissions and Reprints

Definition

Patienten mit Diabetes mellitus Typ 2, aber auch Patienten mit metabolischem Syndrom (also bei noch normaler Glukosetoleranz) weisen sehr häufig eine typische Fettstoffwechselstörung auf. Diese durch Erhöhung des Gesamtcholesterins, Erhöhung der Triglyzeride, Erniedrigung des HDL-Cholesterins und das Überwiegen kleiner, dichter LDL-Partikel charakterisierte Fettstoffwechselstörung ist in ihrer Pathogenese eng mit der Insulinresistenz und der abdominellen Adipositas verknüpft. Die klinische Bedeutung der diabetischen Dyslipoproteinämie leitet sich vor allem daraus ab, dass es sich hierbei um einen wichtigen kardiovaskulären Risikofaktor

Die diabetische Dyslipidämie ist ein bedeutender kardiovaskulärer Risikofaktor.
handelt. 

Literatur

  • 1 Grundy S M, Hansen B, Smith S C et al. Clinical management of metabolic syndrome. Report of the American Heart Association / National Heart, Lung, and Blood Institute / American Diabetes Association Conference on scientific issues related to management.  Circulation. 2004;  109 551-556
    CrossrefSearch in Google Scholar
  • 2 Taskinen M R. Diabetic dyslipidaemia: from basic research to clinical practice.  Diabetologia. 2003;  46 733-749
    CrossrefSearch in Google Scholar
  • 3 Austin M A, King M C, Vranizan K M et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.  Circulation. 1990;  82 495-506
    CrossrefSearch in Google Scholar
  • 4 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.  Circulation. 2002;  106 3143-3421 ,  (Risikokalkulator: www.chd-taskforce.com)
    Search in Google Scholar
  • 5 Grundy S M, Cleeman J I, Merz C N et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.  Arterioscler Thromb Vasc Biol. 2004;  24 e149-e161
    CrossrefSearch in Google Scholar
  • 6 American Diabetes Association . Standards of medical care in diabetes. Position Statement.  Diabetes Care. 2005;  28 (Suppl 1) 4-37
    CrossrefSearch in Google Scholar
  • 7 Deutsche Diabetes-Gesellschaft . Praxisleitlinien der Deutschen Diabetes-Gesellschaft.  Diabetes und Stoffwechsel. 2002;  11 3-4
    Search in Google Scholar
  • 8 Parhofer K G, Laubach E, Geiß H C et al. Effect of glucose control on lipid levels in patients with type 2 diabetes.  Deutsche Med Wochenschr. 2002;  127 958-962
    Thieme ConnectSearch in Google Scholar
  • 9 Parhofer K G, Otto C, Geiss H C et al. Effect of Pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 – results of a pilot study.  Exp Clin Endocrinol Diabetes. 2005;  113 49-52
    Thieme ConnectSearch in Google Scholar
  • 10 Parhofer K G, Birkeland K I, DeFronzo R et al. Irbesartan has no short-term effect on insulin resistance in ­hypertensive patients with additional cardiometabolic risk factors (i-RESPOND).  Int J Clin Pract. 2010;  64 160-168
    CrossrefSearch in Google Scholar
  • 11 Baigent C, Keech A, Kearney P M for the Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and ­safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.  Lancet. 2005;  366 1267-1278
    CrossrefSearch in Google Scholar
  • 12 Frost R J, Otto C, Geiss H C et al. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.  Am J Cardiol. 2001;  87 44-48
    Search in Google Scholar
  • 13 Geiss H C, Dietlein M, Parhofer K G. Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.  Exp Clin Endocrinol Diabetes. 2003;  111 322-324
    Thieme ConnectSearch in Google Scholar
  • 14 Keech A, Simes R J, Barter P FIELD study investigators et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.  Lancet. 2005;  366 1849-1861
    CrossrefSearch in Google Scholar
  • 15 Taylor A J, Sullenberger L E, Lee H J et al. Arterial Biology for the Investigation of the Treatment Effects of ­Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.  Circulation. 2004;  110 3512-3517
    CrossrefSearch in Google Scholar
  • 16 Taylor A J, Villines T C, Stanek E J et al. Extended-release niacin or Ezetimibe and carotid intima-media thickness.  N Engl J Med. 2009;  361 2113-2122
    CrossrefSearch in Google Scholar

Prof. Dr. K. G. Parhofer

Klinikum der Universität München – Großhadern · Medizinische Klinik II

Marchioninistraße 15

81377 München

Email: Klaus.Parhofer@med.uni-muenchen.de